Veravas announced it raised $20.6 Million in an initial filing from an offering of $26.4 Million

Company

Location

About

Veravas™ is transforming laboratory diagnostics by making early detection of disease possible in any sample type including saliva. This technology will have a profound impact on the performance and speed of development and facilitates the use of saline oral rinse (saliva-based) as an alternative to serum or plasma. Using this technology, Veravas is bringing high value tests to market in areas such as neurological diseases, cancer, cardiovascular, and infectious disease that have not been previously possible. To learn more about our technologies and clinical applications, visit veravas.com